Menu

Examples of successful collaboration

Daewoong Pharma focuses on win-win with our partners.
Daewoong Pharma has many good examples of open collaboration.

BIOTECH

Co-management/development Partnering for Licensing Out

more

Venture

Production of Luphere with the introduction of sustained-release platform technology

more

Venture

Joint-development of stem cells with the venture company Kangstem Biotech

more

University

Academic-industrial joint-development of spine fusion implant

more

Government agencies

Development of 3D printing medical device for BGS-7 (bioactive glass material)

more

Hospital (clinicians)

Development of new products through collaboration with experts in the fields of wound healing

more

Global company

Foundation of JV with Indonesian company Infion

more
next
previous

Provision of core competencies

Daewoong Pharma provides various solutions that will help lead
your ideas/projects to success through open collaboration.

  • Provision of materials
  • Production support
  • Investigator-initiated research programs
  • Network provided
  • Access to research facilities

Laries

We can provide more than 100,000 in-house compounds to
study mechanism of action of new target and find effective materials

  • Fragment library

    (molecular weight: 350 or less, suitable for effective scaffold excavation, concentration: 10 to 50 mM)

  • Ion channel-dedicated compounds library

    (concentration: 10 mM)

  • Kinase inhibitor dedicated library

    (concentration: 10 mM)

Stem cells

We can provide the stem cells and growth factors suitable according to the research stage.

Technology

Technology

Daewoong pharma which has a variety of specialized preparation such as depot injection, pills develops formulations optimized for customer needs.

Experience

Experience

Daewoong pharma provides CDMO solution based on skilled experience and know-how accumulated over 70 years

Quality-oriented

Quality-oriented

Daewoong pharma which considers quality first operates the facilities and quality management system in the level of cGMP/EU-GMP

Support from Daewoong Pharma

  • Research fund required for clinical/nonclinical research

  • Review of research plan from Daewoong Pharma IIS Approval Committee

  • Support for clinical medicine and medical supplies(depending on the research subject)

  • Support for statistical processing (clinical trial plans and reports created) (disparity depending on the research subject)

Benefits to researchers

  • Broad financial support for various clinical areas

  • Advisory role of research-led clinical practice based on Daewoong’s clinical competence

  • Contribution of researchers’ performance as a result of clinical studies and further clinical improvement

  • TILLOTTS Pharma
  • Astrazeneca
  • IPsen
  • Almirall
  • Aptalis
  • Bruschettini
  • Recipharm
  • Meda
  • Kyowa kirin
  • Onxeo
  • Ethyphram
  • VVRIX
  • Stiefel
  • BMS
  • BMS
  • Eleison
  • Eleison
  • HBN
  • Janssen
  • menarini
  • Merck
  • PRP
  • Daiichi-sankyo
  • Novartis
  • Sato
  • Merap
  • Astellas
  • Emcure
  • synthon
  • Sumitomo Dainippon
  • Sandoz
  • Kaken
  • Mitsubishi tanabe
  • Asia Pharma
  • Cipharma
  • P.T Infion
  • OUBARI HABBOUSH
  • Vietha Pharma
  • Medicas
  • Bago
  • Eisai
  • Supernus
  • Takeda
  • Probiomed
  • ABDiibrahim
  • Comedix
  • Egy-Tec
  • TKJ pharmaceuticals
  • Alphaeon
  • Strathspey crown
  • Evolus
  • Alvils
  • Pharm sintez
  • GPC
  • Autotelic LLC
DW-LAB

DW-LAB

Domestic/foreign Daewoong Pharma Research Institute is opened to Daewoong Pharma’s collaborators. It’s located in Korea, China, India and Indonesia, and our partners can utilize state-of-the-art facilities.

Stem cell GMP

Stem cell GMP

GMP facility dedicated to stem cells in Daewoong Pharma Bio Research is to produce a stem cell clinical sample and products built on the needs of researchers in the field of regenerative medicine, which is open space for Daewoong Pharma’s partners.

Smart Office

Smart Office

Daewoong Pharma Bio Center implemented smart office environment to enable researchers actively to exchange by applying smart office concept, and collaboration targets can use in conjunction with DW Lab.

Partnership compensation system

step01 Idea

Standard

  • New product/technology development concept and document of proof
  • Required : Scientific feasibility
  • Options : Marketability, Feasibility

Procedures

  1. 1. 1st rapid review > Confidentiality Agreement(CDA)
  2. 2. 2nd review > Feasibility test
  3. 3. Joint research/Introduction contract

Performance allocation

  • Feasibility expenses : Covered by Daewoong Pharma
  • Joint research expenses : Negotiation
  • Patent rights : Joint
  • Exclusive license : Daewoong Pharma royalty fee
step02 Search

Standard

  • Possession of efficacy by realizing the concept, POC, basic toxicity data

Procedures

  1. 1. 1st rapid review > Confidentiality Agreement(CDA)
  2. 2. 2nd review > Conclusion of MTA > Feasibility test and Due Diligence
  3. 3. Joint research/Introduction contract

Performance allocation

  • MTA evaluation : Covered by Daewoong Pharma
  • Joint research expenses : Negotiation
  • Patent rights : Joint
  • Exclusive license : Daewoong Pharma royalty fee
step03 Development Early stage

Standard

  • Nonclinical toxicity ~ clinical phase 1

Procedures

  1. 1. 1st rapid review > Confidentiality Agreement(CDA) > Technology/product presentation
  2. 2. 2nd review > MTA or Due Diligence
  3. 3. Introduction or conclusion of joint research agreement

Performance allocation

  • Development cost : Mutual Negotiation
  • Exclusive license : Daewoong Pharma(territory negotiation) royalty fee
step04 Development Last stage

Standard

  • Clinical phase 2 ~ 3

Procedures

  1. 1. 1st rapid review > Confidentiality Agreement(CDA) > Technology/product presentation
  2. 2. 2nd review > MTA or Due Diligence
  3. 3. Introduction and conclusion of joint research

Performance allocation

  • Development cost : Mutual Negotiation
  • Exclusive license : Daewoong Pharma(territory negotiation) royalty fee
step05 Commercialization

Standard

  • Permission submission preparation stage

Procedures

  1. 1. 1st rapid review > Confidentiality Agreement(CDA) > Technology/product presentation
  2. 2. 2nd review > MTA or Due Diligence
  3. 3. Introduction and conclusion of joint research

Performance allocation

  • Development cost : Mutual Negotiation
  • Exclusive license : Daewoong Pharma(territory negotiation) royalty fee